Back to Cancer Australia's website

Cancer Australia

Select a guideline

Recommendations for Aromatase inhibitors as adjuvant endocrine therapy

Acknowledgements

Membership of the NBCC** Hormonal Therapies Guideline Working Group

This guideline was developed by a multidisciplinary working group convened by the National Breast Cancer Centre**.

Associate Professor Martin Stockler Medical Oncologist (Chair)
Dr Fran Boyle Medical Oncologist
Dr Nicholas Wilcken Medical Oncologist
Professor Ian Olver Medical Oncologist
Mr David Oliver Surgeon
Dr Melissa Bochner Surgeon
Dr Liz Kenny Radiation Oncologist
Ms Lee Millard Breast Care Nurse
Dr Julie Thompson General Practitioner
Ms Susan Timbs Consumer Representative

NBCC** Staff

Dr Elmer Villanueva, Ms Rosemary Vagg, Dr Alison Evans, Mr Andy Moore, Dr Karen Luxford, Dr Helen Zorbas

Full details of trial results are provided in the document Aromatose Inhibitors as Adjuvant Therapy for Post-Menopausal Women with Hormone Receptor-Positive Early Breast Cancer: Evidence Summary which can be accessed via the NBCC** website at www.nbcc.org.au

** In February 2008, National Breast Cancer Centre (NBCC), incorporating the Ovarian Cancer Program, changed its name to National Breast and Ovarian Cancer Centre (NBOCC). In July 2011, NBOCC amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.

Pharmaceutical Benefits Scheme Indications for drugs mentioned in this guideline

As of July 2006. For updates after this date go to http://www.health.gov.au/pbs/

Tamoxifen: Treatment of hormone-dependent breast cancer.
Anastrozole: Treatment of hormone-dependent breast cancer in post-menopausal women.  Not subsidised for primary prevention of breast cancer.
Letrozole: Treatment of hormone-dependent advanced breast cancer in post-menopausal women.  Not subsidised for primary prevention of breast cancer.
Exemestane: Treatment of hormone-dependent advanced breast cancer in post-menopausal women with disease progression following treatment with tamoxifen citrate.  Not subsidised for primary prevention of breast cancer.

Development process

Priority topic areas for NBOCC guideline development are determined in consultation with key stakeholders including experts in relevant disciplines and consumer representatives. A specific multidisciplinary Working Group, including consumers, is established for each topic identified and is involved in all aspects of guideline development. A systematic evidence review is undertaken for each guideline. All members are asked to declare any conflicts of interest and these declarations are recorded.  The content of the guideline is not influenced by any external funding body. The guideline is reviewed externally by key stakeholders and the wider community and endorsement is sought from relevant professional colleges and groups in Australia.

Recommendations for aromatase inhibitors as adjuvant endocrine therapy for post-menopausal women with hormone receptor-positive early breast cancer was prepared and produced by:

National Breast and Ovarian Cancer Centre
Level 1, Suite 103, 355 Crown Street Surry Hills NSW 2010
Tel: +61 2 9357 9400 Fax: +61 2 9357 9477 Frecall 1800 624 973
Website: www.nbocc.org.au

© National Breast Cancer Centre 2006
ISBN Print: 978-1-74127-010-5 Online: 978-174127-011-2 CIP: 616.99449061

This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be reproduced by any process without prior written permission from the National Breast Cancer Centre. Requests and enquiries concerning reproduction and rights should be addressed to the Corporate Communications Manager, National Breast and Ovarian Cancer Centre.

Recommended citation
National Breast Cancer Centre. Recommendations for aromatase inhibitors as adjuvant endocrine therapy for post-menopausal women with hormone receptor-positive early breast cancer. National Breast Cancer Centre, Camperdown, NSW, 1450.

Disclaimer
National Breast and Ovarian Cancer Centre does not accept any liability for any injury, loss or damage incurred by use of or reliance on the information. National Breast and Ovarian Cancer Centre develops material based on the best available evidence, however it cannot guarantee and assumes no legal liability or responsibility for the currency or completeness of the information.

National Breast and Ovarian Cancer Centre is funded by the Australian Government Department of Health and Ageing.

Published using CeCC Docbook Manager